Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer

BACKGROUND: Despite an enormous research effort, patients diagnosed with advanced colorectal cancer (CRC) still have low prognosis after surgical resection and chemotherapy. The major obstacle for CRC treatment is chemoresistance to front line anti-cancer drugs, such as 5-fluorouracil (5-FU) and oxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xianjun, Hou, Wenhou, Liu, Xin, Chai, Jie, Guo, Hongliang, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713438/
https://www.ncbi.nlm.nih.gov/pubmed/33292253
http://dx.doi.org/10.1186/s12935-020-01668-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713438/
https://www.ncbi.nlm.nih.gov/pubmed/33292253
http://dx.doi.org/10.1186/s12935-020-01668-z

Ejemplares similares